Tysabri and PML: What the Evidence Shows About Risk and Monitoring

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of Health Communication and Occupational Risk

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This risk has been recognized and studied for over a decade, with ongoing pharmacovigilance efforts continuously refining our understanding of who is most at risk and how to monitor for early signs. This page provides a concise summary of the evidence on Tysabri-associated PML, including patient history, onset timeline, and key safety considerations.

Tysabri Pharmacology and PML Risk

Tysabri (natalizumab) is a biologic therapy approved for the treatment of relapsing forms of multiple sclerosis (MS) and Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus (JCV). The following narrative synthesizes evidence from FDA-approved labeling to describe the clinical presentation, mechanistic links, risk factors, and settlement-related considerations for affected patients. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of the JC virus, which infects oligodendrocytes and causes progressive demyelination. Clinical symptoms may include cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis is confirmed through brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Early recognition is critical, as prompt discontinuation of Tysabri may improve outcomes.

Mechanistic Pathways and Risk Factors

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing lymphocyte migration into the central nervous system. This mechanism reduces inflammatory activity in MS but also impairs immune surveillance, creating an environment permissive for JCV reactivation. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 MS patients treated for a median of 120 weeks, both of whom had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML. Common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and urinary tract infections. The primary mechanism linking Tysabri to PML involves reduced immune surveillance in the central nervous system. By blocking lymphocyte trafficking, Tysabri decreases the number of CD4+ and CD8+ T cells in the brain, which are essential for controlling JCV replication. This immunosuppressive effect allows latent JCV to reactivate and cause lytic infection of oligodendrocytes. The risk is further amplified in patients with pre-existing anti-JCV antibodies, longer treatment duration, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Settlement Criteria

The FDA-approved labeling for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. The labeling advises healthcare professionals to consider these factors in the context of expected benefit when initiating and continuing treatment. Patients must be monitored for any new signs or symptoms suggestive of PML, and Tysabri dosing should be withheld immediately at the first indication of PML. The drug is only available through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed risk-benefit discussions and appropriate monitoring. For patients who develop PML after Tysabri use, legal settlements may consider several factors. The adequacy of warnings is central: the boxed warning clearly states the risk, but questions may arise about whether prescribers and patients were fully informed of the magnitude of risk, especially in the context of combination therapy with other immunosuppressants. The timeline between exposure and documented harm is also critical. PML typically occurs after prolonged treatment, with the highest risk after two years of therapy. In clinical trials, cases were observed after a median of 120 weeks in MS patients and after eight doses in a Crohn's disease patient. Settlement criteria may evaluate whether the patient had identifiable risk factors (e.g., anti-JCV antibody positivity, prior immunosuppressant use) and whether monitoring protocols were followed. The severity of outcome—death or severe disability—is a key determinant of compensation. Patients or their families may seek damages for medical expenses, lost income, and pain and suffering.

Conclusion

Tysabri-associated PML is a rare but devastating adverse event with a clear mechanistic basis and well-defined risk factors. FDA labeling provides explicit warnings and monitoring recommendations, but the severity of outcomes underscores the importance of careful patient selection and adherence to risk mitigation strategies. For affected individuals, settlement considerations hinge on the adequacy of warnings, the presence of risk factors, and the timeline of exposure to harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and what is its link to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to reduced immune surveillance in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the settlement criteria for Tysabri-related PML?

Settlement criteria typically include documented Tysabri exposure, confirmed PML diagnosis, presence of risk factors (anti-JCV antibodies, long treatment duration, prior immunosuppressants), and severity of outcome (death or severe disability). The adequacy of warnings and adherence to monitoring protocols are also considered.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.